Pharvaris has secured approximately $175 million through a public offering of ordinary shares, with funds expected to support the continued development of its oral bradykinin B2 receptor antagonist therapies for hereditary angioedema (HAE) and related conditions.

The Switzerland-based company is advancing deucrictibant, a selective oral B2 receptor antagonist currently in late-stage trials for both on-demand and prophylactic use in HAE. This rare genetic disease, characterised by recurring and potentially life-threatening swelling, affects approximately 1 in 50,000 people and remains an area of ongoing clinical need. Pharvaris is also exploring applications for acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), a condition with overlapping pathophysiology.

Current standard-of-care treatments for HAE are largely injectable, including monoclonal antibodies and plasma-derived therapies. Pharvaris is among a new generation of companies aiming to simplify disease management by offering oral alternatives without compromising on efficacy.

The capital raise included 8.25 million ordinary shares priced at $20.00 each and 500,000 pre-funded warrants sold to a single investor. The offering was upsized due to demand, and the company has granted underwriters a 30-day option to purchase up to 1.3 million additional shares. The transaction is expected to close around July 24, subject to customary conditions.

All shares and pre-funded warrants in the offering are being sold by Pharvaris. The company is listed on Nasdaq under the ticker PHVS. Morgan Stanley, Leerink Partners, Cantor, Oppenheimer & Co., and Van Lanschot Kempen acted as joint book-running managers for the offering.

The funding will support Pharvaris’ ongoing development of deucrictibant as it moves toward potential regulatory submission. The candidate is designed to block the bradykinin B2 receptor and reduce vascular permeability—addressing the root cause of swelling in both HAE and AAE-C1INH.

With growing demand for oral therapies in rare disease areas, Pharvaris’ platform reflects a broader trend toward more convenient, patient-centric treatment models in immunology and genetic conditions.